Five-fraction stereotactic magnetic resonance-guided adaptive radiotherapy targeting the primary tumor in metastatic pancreatic cancer

doi:10.3748/wjg.117832

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 29

This Article

(17)

(18)

(0)

(1)

(556)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Aug 7, 2026; 32(29): 117832
Published online Aug 7, 2026. doi: 10.3748/wjg.117832

Table 3 Treatment characteristics, n (%)

Treatment characteristics
Chemotherapy preceding MRgRT
Number of patients received chemotherapy	22 (92)
Median duration of chemotherapy (months)	7
Median number of cycles	12 cycles
(m)FOLFIRINOX	16 (67)
Gem/nabPac	4 (17)
Liposomal irinotecan + 5-FU and folinic acid (NAPOLI)	2 (8)
No chemotherapy	2 (8)
Radiotherapy
Median total dose, Gy (range)	33 (33-40)
33 Gy/SIB 40 Gy	11 (46)
33 Gy	13 (54)
Gross tumor volume, median range (cc)	44 (12-101)
Clinical target volume, median range (cc)	214 (81-583)
Optimized planning target volume, median range (cc)	248 (65-662)
Metastasis-directed therapy	4 (17)
SBRT or brachytherapy	3 (13)
Resection of liver metastasis	1 (4)
Post-RT chemotherapy	19 (83)

MRgRT: Magnetic resonance-guided radiotherapy; FOLFIRINOX: Folinic acid, fluorouracil, irinotecan, oxaliplatin; Gem/nabPac; Gemcitabin/nab-paclitaxel; 5-FU: 5-fluorouracil; Gy: Gray; SIB: Simultaneous integrated boost; SBRT: Stereotactic body radiotherapy; RT: Radiotherapy.

Full Size Table

Citation: Schumann MA, Gaasch A, Boyaci S, Fuchs F, Walter F, Marschner SN, Eze C, Westphalen CB, Holch JW, Beyer G, Kunz WG, Mayerle J, Niyazi M, Belka C, Corradini S, Rogowski P. Five-fraction stereotactic magnetic resonance-guided adaptive radiotherapy targeting the primary tumor in metastatic pancreatic cancer. World J Gastroenterol 2026; 32(29): 117832
URL: https://www.wjgnet.com/1007-9327/full/v32/i29/117832.htm
DOI: https://dx.doi.org/10.3748/wjg.117832

Schumann MA, Gaasch A, Boyaci S, Fuchs F, Walter F, Marschner SN, Eze C, Westphalen CB, Holch JW, Beyer G, Kunz WG, Mayerle J, Niyazi M, Belka C, Corradini S, Rogowski P. Five-fraction stereotactic magnetic resonance-guided adaptive radiotherapy targeting the primary tumor in metastatic pancreatic cancer. World J Gastroenterol 2026; 32(29): 117832 [DOI: 10.3748/wjg.117832]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.